Progress of treatment-related hemophagocytic syndrome
10.3760/cma.j.cn115356-20210307-00043
- VernacularTitle:治疗相关噬血细胞综合征研究进展
- Author:
Weibin ZHUO
1
;
Chenghong WANG
;
Zhiqiang SUN
Author Information
1. 南方医科大学深圳医院血液科，广东 深圳 518100
- Keywords:
Lymphohistiocytosis, hemophagocytic;
Immune checkpoint inhibitors agents;
Ibrutinib;
Lamotrigine
- From:
Journal of Leukemia & Lymphoma
2021;30(11):695-697
- CountryChina
- Language:Chinese
-
Abstract:
Hemophagocytic syndrome (HPS) is a rare, life-threatening inflammatory response syndrome characterized by overactivation of the immune system, which leads to organ damage. Secondary HPS is usually triggered by infection, tumor and autoimmune disease. It has been clinically found that many HPS-like manifestations also occur during drug therapy. This article reviews the related progress of HPS induced by immune checkpoint inhibitors, ibrutinib and lamotrigine, in order to provide a guidance for clinical practice.
